Pfizer 2015 Annual Report Download - page 132

Download and view the complete annual report

Please find page 132 of the 2015 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 134

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
2015 Financial Report
131
Quarter
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) First Second Third Fourth
2014
Revenues $11,353 $12,773 $12,361 $13,118
Costs and expenses(a) 8,448 8,689 8,793 11,185
Restructuring charges and certain acquisition-related costs(b) 58 81 (19)130
Income from continuing operations before provision/(benefit) for taxes on income 2,847 4,003 3,587 1,803
Provision/(benefit) for taxes on income 582 1,082 911 545
Income from continuing operations 2,265 2,921 2,676 1,257
Discontinued operations—net of tax 73 — (3) (21)
Net income before allocation to noncontrolling interests 2,338 2,921 2,672 1,236
Less: Net income attributable to noncontrolling interests 9 9 68
Net income attributable to Pfizer Inc. $ 2,329 $2,912 $2,666 $1,228
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.35 $0.46 $0.42 $0.20
Discontinued operations—net of tax 0.01 —— —
Net income attributable to Pfizer Inc. common shareholders $ 0.36 $0.46 $0.42 $0.20
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $ 0.35 $0.45 $0.42 $0.20
Discontinued operations—net of tax 0.01 —— —
Net income attributable to Pfizer Inc. common shareholders $ 0.36 $0.45 $0.42 $0.19
Cash dividends paid per common share $ 0.26 $0.26 $0.26 $0.26
Stock prices
High $32.96 $32.69 $31.31 $33.12
Low $29.66 $28.77 $27.87 $27.51
(a) The fourth quarter of 2014 reflects historically higher costs in Cost of sales, Selling, informational and administrative expenses and Research and development
expenses.
(b) The fourth quarter of 2014 reflects higher employee termination costs.
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may
not agree to the total for the year.